Status:
COMPLETED
Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF
Lead Sponsor:
Humanity and Health Research Centre
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
In Chronic hepatitis B (CHB) patients receiving long-term sequential Neucleos(t)ides(NAs), majority of these CHB patients experienced drug resistance and switched to Tenofovir disoproxil fumaratate(TD...
Detailed Description
Tenofovir disoproxil fumarate(TDF) have been associated with renal toxicity and reduced bone mineral density. Tenofovir alafenamide(TAF) is a novel tenofovir prodrug that reduces tenofovir plasma conc...
Eligibility Criteria
Inclusion
- Chronic hepatitis B,
- Antiviral experienced,
- Currently on long term TDF anti-HBV treatment,
- HBV DNA \< 6 log IU/ml (LLOD)
- Able to sign the consent form of anticipating in the study
Exclusion
- Co-infected with HCV, HIV or other viral hepatitis,
- Diagnosis of HCC
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2024
Estimated Enrollment :
575 Patients enrolled
Trial Details
Trial ID
NCT03356834
Start Date
December 1 2017
End Date
October 31 2024
Last Update
March 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Humanity and Health GI and Liver Centre
Hong Kong, Hong Kong, Hong Kong, 00852